Enhanced Treatment of Hepatocellular Carcinoma: Review of Novel mRNA Approach in China

This study on hepatocellular carcinoma (HCC) was conducted by a multidisciplinary team from prominent Chinese institutions, including the Department of Transfusion Medicine and the Hepatobiliary and Pancreatic Surgery departments of Nanchang University and affiliated hospitals.  The study authors hypothesized that the co-expression of the genes CRHBP and CFHR3 plays a critical role in inhibiting the malignant progression of HCC. Furthermore, leveraging lipid nanoparticle (LNP) technology functionalized with the HCC-targeting peptide SP94 for the delivery of CRHBP and CFHR3 mRNAs could offer a novel and effective therapeutic strategy for HCC.

Study Design and Methods